Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis

Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis

IntroductionThis meta-analysis was designed to compare the long-term outcomes of first-line cyclin-dependent kinase 4/6 (CDK4/6) inhibitors plus endocrine therapy (ET) versus ET in patients with HR+/HER2-metastatic or advanced breast cancer (BC).Materials and methodsFour databases (Medline, Embase,...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaojian Wang, Xinyi Liang, Chenchen Li, Mengtian Qin, Jianyu Wu, Yuechen Qin, Yue Zou, Haijian Zeng, Chunlan Li, Xiaomeng Huang, Haiyun Tao, Jieru Quan, Xiao Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Pharmacology
Subjects:
breast cancer
metastatic
endocrine therapy
CDK4/6 inhibitors
progression-free survival
overall survival
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1600892/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1600892/full

Similar Items